(Q37930709)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Iris Amitay-Laish

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Salomon M Stemmer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

386-395

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21910796%20AND%20SRC:MED&resulttype=core&format=json

Indications for imatinib mesylate therapy and clinical management

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Chemotherapeutic agents and the skin: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Is imatinib mesylate a promising drug in systemic sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib mesylate treatment of nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Practical management of patients with chronic myeloid leukemia receiving imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Skin and oral lesions associated to imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Cutaneous reactions to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib treatment: specific issues related to safety, fertility, and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib-associated hyperpigmentation, a side effect that should be recognized

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib mesylate and gray hair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib mesylate causes hypopigmentation in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib: a designer drug, another cutaneous complication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Pityriasis rosea associated with imatinib (STI571, Gleevec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Stevens-Johnson syndrome after treatment with STI571: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Managing cutaneous reactions to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Sti571-induced Stevens-Johnson Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Mycosis fungoides-like reaction in a patient treated with Gleevec

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Follicular mucinosis associated with imatinib (STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

The toxicities of modern targeted therapies: learning from the price of progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Severe adverse cutaneous reactions to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2011.01431.X